TimesSquare Capital Management LLC lowered its holdings in NexImmune, Inc. (NASDAQ:NEXI – Get Rating) by 52.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 216,391 shares of the company’s stock after selling 238,159 shares during the quarter. TimesSquare Capital Management LLC owned 0.95% of NexImmune worth $998,000 as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of NEXI. BlackRock Inc. boosted its holdings in NexImmune by 150.4% in the third quarter. BlackRock Inc. now owns 812,664 shares of the company’s stock valued at $12,304,000 after purchasing an additional 488,140 shares during the last quarter. First Manhattan Co. purchased a new stake in shares of NexImmune in the third quarter worth about $2,227,000. Kingdon Capital Management L.L.C. acquired a new stake in NexImmune during the third quarter worth about $1,786,000. Geode Capital Management LLC raised its position in NexImmune by 87.4% during the third quarter. Geode Capital Management LLC now owns 212,431 shares of the company’s stock valued at $3,216,000 after acquiring an additional 99,095 shares in the last quarter. Finally, Edgewood Management LLC acquired a new position in NexImmune in the third quarter valued at approximately $848,000. 45.45% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ NEXI traded down $0.18 during trading on Monday, hitting $2.79. The company had a trading volume of 1,495 shares, compared to its average volume of 185,621. The firm has a market capitalization of $63.73 million, a price-to-earnings ratio of -1.07 and a beta of 0.92. The firm’s fifty day simple moving average is $2.81. NexImmune, Inc. has a fifty-two week low of $1.72 and a fifty-two week high of $26.50.
NEXI has been the topic of a number of recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of NexImmune in a report on Friday, April 1st. Zacks Investment Research upgraded NexImmune from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research note on Thursday, February 24th. Barclays increased their price target on NexImmune from $4.00 to $7.00 and gave the stock an “overweight” rating in a research report on Friday, April 1st. Finally, Raymond James cut their price objective on NexImmune from $21.00 to $13.00 and set an “outperform” rating for the company in a research report on Tuesday, February 22nd.
In other NexImmune news, CEO Kristi Jones purchased 10,000 shares of the stock in a transaction that occurred on Tuesday, March 29th. The shares were purchased at an average cost of $3.74 per share, for a total transaction of $37,400.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Sol J. Barer acquired 30,000 shares of the company’s stock in a transaction that occurred on Friday, March 18th. The shares were acquired at an average cost of $2.11 per share, with a total value of $63,300.00. The disclosure for this purchase can be found here. Insiders have acquired 128,978 shares of company stock valued at $378,359 in the last three months.
About NexImmune (Get Rating)
NexImmune, Inc, a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.
- Get a free copy of the StockNews.com research report on NexImmune (NEXI)
- Banking On Bank Of America
- Major Shareholder Bets Big On Nielson Holdings plc
- Tapestry Stock is a Value Play Down Here
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
Receive News & Ratings for NexImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NexImmune and related companies with MarketBeat.com's FREE daily email newsletter.